HNSAN Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Confirmatory Clinical Efficacy (ConfideS/PAES)Robust, statistically significant ConfideS and positive PAES data materially reduce clinical uncertainty around imlifidase. Durable efficacy and lower dialysis dependence underpin stronger regulatory conversion prospects and long-term physician adoption, supporting sustainable commercial uptake if approvals proceed.
Material Out‑licensing Upfront Improves RunwayThe EUR 110m upfront meaningfully extends near‑term liquidity ahead of U.S. regulatory milestones, lowering immediate refinancing pressure. This structural cash infusion provides time to execute launch preparations and pursue approvals without forcing urgent dilutive financing, improving execution odds over the next 6–12 months.
Large U.S. Market Opportunity And Launch ReadinessA sizeable ~$2bn addressable U.S. market plus focused engagement of the top transplant centers represents durable revenue potential if uptake occurs. Ongoing commercial hiring and center profiling indicate structural readiness to scale sales once reimbursement and approvals align, supporting long‑term growth prospects.
Bears Say
Weak Balance Sheet And High LeverageNegative equity combined with sizable debt materially constrains financial flexibility and increases refinancing and solvency risk if operating losses persist. Structural leverage limits strategic optionality for investments or setbacks, making timely commercial success or recurring partner payments critical for stability.
Persistent Negative Cash Flow And BurnSustained, large operating cash deficits indicate ongoing reliance on external funding unless margins improve or revenues scale. This chronic cash burn can force recurring partnerships, milestone sales, or dilutive financings, constraining long‑term capital allocation and potentially delaying investments in commercialization.
Revenue Decline With Large Operating LossesA sharp revenue drop and very large negative margins show the business lacks scale to cover elevated SG&A and launch costs. Even with attractive product gross margins, persistent top‑line weakness and widened operating losses lengthen the path to profitability and heighten dependence on successful new market launches.
Hansa Biopharma AB News
HNSAN FAQ
What was Hansa Biopharma’s price range in the past 12 months?
Currently, no data Available
What is Hansa Biopharma’s market cap?
Hansa Biopharma’s market cap is $7.22B.
When is Hansa Biopharma’s upcoming earnings report date?
Hansa Biopharma’s upcoming earnings report date is Nov 05, 2026 which is in 103 days.
How were Hansa Biopharma’s earnings last quarter?
Hansa Biopharma released its earnings results on Jul 22, 2026. The company reported -$4.599 earnings per share for the quarter, missing the consensus estimate of -$0.605 by -$3.993.
Is Hansa Biopharma overvalued?
According to Wall Street analysts Hansa Biopharma’s price is currently Undervalued.
Does Hansa Biopharma pay dividends?
Hansa Biopharma does not currently pay dividends.
What is Hansa Biopharma’s EPS estimate?
Hansa Biopharma’s EPS estimate is 10.35.
How many shares outstanding does Hansa Biopharma have?
Hansa Biopharma has 101,763,220 shares outstanding.
What happened to Hansa Biopharma’s price movement after its last earnings report?
Hansa Biopharma reported an EPS of -$4.599 in its last earnings report, missing expectations of -$0.605. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Hansa Biopharma?
Currently, no hedge funds are holding shares in MX:HNSAN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Hansa Biopharma
Hansa Biopharma AB (publ) is a biopharmaceutical firm dedicated to developing immunomodulatory therapies. Leveraging its unique enzyme technology platform, the company targets treatments that facilitate organ transplants and address rare autoimmune conditions driven by immunoglobulin G (IgG), alongside applications in gene therapy and cancer. Its primary drug candidate, Imlifidase, an enzyme therapy designed to cleave antibodies, is currently undergoing Phase 3 clinical trials for use in patients awaiting sensitized kidney transplants and those with anti-GBM antibody disease. Imlifidase is also in Phase 2 trials for treating antibody-mediated kidney transplant rejection and Guillain Barré syndrome. Further pipeline developments include NiceR (Novel immunoglobulin cleaving enzymes for Repeat dosing) for autoimmune diseases, transplantation, and oncology, as well as EnzE (Enzyme based antibody Enhancement) for cancer immunotherapy. Hansa Biopharma also has a preclinical research partnership with argenx BV, exploring the synergistic potential of their respective IgG-modulating technologies. Established in 2007, the company's headquarters are located in Lund, Sweden.
HNSAN Stock 12 Month Forecast
Average Price Target
$185.03